Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director · Chief Executive Officer | July 10, 2026 | July 14, 2026 |
| Innoviva, Inc.INVA · Entity 4679 | Director | May 22, 2023 | May 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 198,417 |
Reported balance
After 2026-07-10 transaction · row 1
1 source rowRow 1 · 2026-07-10 · Tax withholding · Disposed 14,041 · Balance 198,417 F1: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Innoviva, Inc.
Report date May 22, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,984 |
Reported balance
After 2023-05-22 transaction · row 1
1 source rowRow 1 · 2023-05-22 · Grant · Acquired 16,495 · Balance 58,984 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.64 · Expires 2033-05-21 | Direct | 20,000 |
Reported balance
After 2023-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-22 · Grant · Acquired 10,000 · Balance 20,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 14, 2026 20:18 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 14,041 | $4.26 | $59,814.66 |
DisclosureSEC source: 0001104659-26-083516 · tm2620483-1_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,417 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:46 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 4,919 | $10.54 | $51,846.26 |
DisclosureSEC source: 0001104659-26-029711 · tm269075-1_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,458 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 01:15 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 421,226 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026582 · tm268588-7_4seq1.xml · derivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,226 Underlying: Common Stock · 421,226 shares Expires 2036-03-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:05 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 13,637 | $2.27 | $30,955.99 |
DisclosureSEC source: 0001104659-25-067746 · tm2520709-1_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,377 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 14, 2025 Filed Apr 25, 2025 20:07 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 6,061 | $1.95 | $11,818.95 |
DisclosureSEC source: 0001104659-25-039417 · tm2513168-3_4seq1.xml · nonDerivative · entry 2 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,014 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:15 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010550 · tm255864-1_4seq1.xml · derivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on February 5th of each of 2026, 2027, 2028, and 2029, in each case subject to continuous service through the applicable vesting date. Read SEC document |
| July 10, 2024 Filed Apr 25, 2025 20:07 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | Tax withholdingCommon Stock | 22,925 | $2.68 | $61,439.00 |
DisclosureSEC source: 0001104659-25-039417 · tm2513168-3_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,075 F1 · shares: Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:00 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035723 · tm249071-1_4seq1.xml · derivative · entry 2 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2034-03-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:00 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-035723 · tm249071-1_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:53 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129365 · tm2333426-7_4seq1.xml · derivative · entry 2 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-21 F1 · derivative.exercise_date: Twenty-five percent (25%) of the Stock Options shall vest on July 10th of each of 2024, 2025, 2026, and 2027. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:53 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-129365 · tm2333426-7_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:56 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001104659-23-064214 · tm2316873-5_4seq1.xml · derivative · entry 2 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:56 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064214 · tm2316873-5_4seq1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,984 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:53 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001567619-22-009046 · doc1.xml · derivative · entry 2 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:53 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009046 · doc1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,489 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 14, 2021 Filed May 21, 2021 00:13 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 17,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010826 · doc1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:38 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 1,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-007206 · doc1.xml · nonDerivative · entry 1 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,360 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or March 9, 2022, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 20:45 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantRestricted Stock Units · Derivative | 10,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006868 · doc1.xml · derivative · entry 1 Birx Deborah · CIK 0001849673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,748 Underlying: Common Stock · 10,748 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Common Stock. F2 · derivative.exercise_date: One-half of the restricted stock units will vest on March 9, 2022, and the remainder will vest on March 9, 2023. F2 · derivative.expiration_date: One-half of the restricted stock units will vest on March 9, 2022, and the remainder will vest on March 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.